Prevail Therapeutics raises $75m financing for Parkinson’s gene therapies

This article was originally published here

Prevail Therapeutics has secured $75m series A financing to advance the development of gene therapies for patients with Parkinson’s and other neurodegenerative diseases.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply